DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1976)

Cancer Pain | Landscape & Forecast | Disease Landscape & Forecast

Cancer Pain | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Improving survival among those with advanced cancer along with a high rate of cancer-related pain in this patient population will lead to steady growth in the prevalence of cancer pain in the seven major markets under study throughout the ten-year forecast period. However, treatment of cancer-related pain will not change dramatically over the next decade because of a dearth of new therapies. Indeed, strong opioid analgesics will continue to be the mainstay of treatment for severe types of cancer pain, accounting for more than 90% of major-market drug sales for cancer pain in 2014 and 2024. Overall, we expect only modest growth in the $2 billion cancer pain market throughout our ten-year forecast period. 

Questions Answered:

  • The late-stage pain pipeline is dominated by several strong opioid reformulations in the United States that feature abuse-deterrent properties. What are the expected peak-year sales for these products in the treatment of cancer pain in the U.S. market? Will third-party payers reimburse these newer abuse-deterrent formulations in place of the older opioids? How will political and public pressure in the U.S. market to curb widespread opioid abuse affect uptake of these agents for cancer pain?
  • Several later-stage investigational analgesics, including Immune Pharmaceuticals’ AmiKet, GW Pharmaceutical’s and Otsuka’s Sativex, and Pfizer/Eli Lilly’s and Janssen/Takeda’s anti-nerve growth factor monoclonal antibodies (tanezumab and fulranumab, respectively) have had poor results in clinical trials for cancer pain in recent months. How will these disappointing data affect these agents’ prospects for cancer pain?  How will the outlook for these drugs affect the overall cancer pain market going forward?
  • Several key cancer pain drugs will lose patent protection during the ten-year forecast period. How will these patent expiries affect the overall cancer pain market? Which particular products will see the greatest generic erosion, and when? To what extent will sales of new analgesics offset generic erosion of key products?


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 51 country-specific interviews with thought-leading physicians, including pain specialists, palliative care specialists, anesthesiologists, oncologists, and neurologists.

Epidemiology: Prevalent cases of severe cancer pain, breakthrough cancer pain, neuropathic cancer pain, and metastatic bone pain.

Emerging therapies: Phase II: 7 drugs; Phase III or preregistration: 8 drugs.

Market forecast features: Top-down market features prescription drug treatment for severe, breakthrough, neuropathic, and metastatic bone pain in cancer patients in the seven major markets under study for 2014, with forecast drug sales for 2019 (mid-year) and 2024 (final forecast year).

Table of contents

  • Disease Landscape & Forecast
    • Executive Summary
      • Introduction
        • Key Findings
      • Note About Our Epidemiology Estimates
    • Market Outlook
      • Market Outlook
        • Key Findings
        • Expert Insight
        • Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Cancer Pain?
        • What Factors Are Constraining the Market for Cancer Pain?
      • Drug Class-Specific Trends
        • Opioid Analgesics
        • Dual-Acting Opioid Analgesics
        • Antiepileptic Drugs
        • Antidepressant Drugs
    • Forecast
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Key Findings
        • Expert Insight
        • Disease Overview
      • Key Types of Cancer Pain
        • Severe Cancer Pain
        • Breakthrough Cancer Pain
        • Neuropathic Cancer Pain
        • Metastatic Bone Pain
      • Pathophysiology of Pain Perception
      • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Introduction
        • Key Findings
        • Expert Insight
        • Epidemiology Overview
      • Epidemiology Populations
        • Disease Definition
        • Literature Review
        • Population and Forecast Parameters
        • Key Sources by Geography
        • Population Methods
        • Note About Our Epidemiology Estimates
    • Current Treatment Overview
      • Introduction
        • Key Findings
        • Expert Insight
        • Treatment Overview
      • Treatment Goals
        • Key Physician Insights on Clinical End Points
      • Key Current Therapies
        • Overview
        • Opioid Analgesics
        • Dual-Acting Opioid Analgesics
        • Antiepileptic Drugs
        • Antidepressant Drugs
        • NMDA Receptor Antagonists
        • N-Type Calcium Channel Antagonists
        • Bone-Specific Agents
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Drug Selection
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Attainment of Unmet Needs
        • Current Attainment of Unmet Needs in Cancer Pain
        • Future Attainment of Unmet Needs
    • Emerging Therapies Overview
      • Introduction
        • Key Findings
        • Expert Insight
      • Pipeline Overview
      • Late-Phase Pipeline Analysis
        • Notable Developments in the Late-Phase Pipeline for Cancer Pain
      • Key Emerging Therapies
        • Opioid Analgesics
        • Cannabinoid Receptor Agonists
        • Sodium Channel Modulators
        • Anti-NGF Therapies
      • Early-Stage Pipeline Analysis
        • Notable Developments in the Early-Stage Pipeline for Cancer Pain
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • U.S. Reimbursement Dynamics
        • Reimbursement Dynamics in Cancer Pain in the United States: Current and Future
      • U.S. Access & Reimbursement Considerations for Emerging Therapies
        • Access & Reimbursement Considerations for Emerging Cancer Pain Therapies in the United States
    • Methodology
      • Methdology
        • General Sources of Data
    • Appendix
      • Experts Interviewed
      • Cancer Pain Bibliography

Already a Client? Log in to access this report.

  • Pub Date: November 2015
  • Author(s): Bethany A. Kiernan, PhD; Andrea Witt, PhD
  • Bethany A. Kiernan, is a senior director in the central nervous system/ophthalmology disorders unit of Decision Resources Group. While at Decision Resources Group, Dr. Kiernan has covered the market dynamics of numerous indications, including schizophrenia, depression, migraine, multiple sclerosis, epilepsy, and other disorders. Dr. Kiernan’s previous experience includes eight years of scientific research conducted at Tufts University School of Medicine, Case Western Reserve University, and the College of the Holy Cross. Dr. Kiernan earned her degree from Case Western Reserve University.

  • Andrea S. Witt, is Therapy Leader of the Central Nervous System and Ophthalmology Disorders Portfolio at Decision Resources Group where she oversees a team of 14 Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.  Dr. Witt has been with Decision Resources Group for over 12 years, following CNS markets and trends. Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her degree.

Purchase Report

Recent reports:
You may also be interested in: